What are GLP-1 Receptor Agonists?
Definition
GLP-1 receptor agonists (GLP-1 RAs) are a class of peptide drugs that mimic the incretin hormone glucagon-like peptide-1. They bind to and activate the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. Major examples include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound).
Detailed Explanation
Native GLP-1 is a 30-amino-acid peptide hormone secreted by intestinal L-cells in response to food intake. It has a plasma half-life of only 2-3 minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). The development of therapeutic GLP-1 RAs required engineering peptides that resist DPP-4 degradation while maintaining receptor binding. Exenatide (Byetta), the first approved GLP-1 RA in 2005, was based on exendin-4, a peptide from Gila monster venom with 53% homology to human GLP-1. Liraglutide achieved a longer half-life (13 hours) through fatty acid acylation, enabling once-daily dosing. Semaglutide pushed this further with a C-18 fatty acid chain and amino acid substitutions, achieving a half-life of approximately 7 days and enabling weekly dosing.
The pharmacogenomics of GLP-1 RAs is an active area of research. Genetic variants in the GLP1R gene (encoding the GLP-1 receptor) can influence drug response. The variant rs6923761 (Gly168Ser) has been associated with differences in weight loss response to GLP-1 RAs in some studies. Variants in TCF7L2 (rs12255372, rs7903146) — the strongest common genetic risk factors for type 2 diabetes — affect the incretin signaling pathway that GLP-1 RAs target. Additionally, variants in genes involved in gastric motility, appetite regulation (FTO, MC4R), and beta-cell function can modulate treatment outcomes. Understanding these variants helps predict which patients will respond best to GLP-1 RA therapy.
PepFold's computational pipeline can design GLP-1-related peptide candidates based on a patient's pharmacogenomic profile. By analyzing variants in GLP1R, TCF7L2, and related genes, the system generates peptide sequences optimized for the specific receptor conformation predicted by the patient's genotype. This approach represents the convergence of two major pharmaceutical trends: the commercial success of GLP-1 RA peptide drugs and the growing clinical adoption of pharmacogenomic-guided prescribing.
Related Terms
Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically between 2 and 50 residues in length. They occupy a unique niche between small-molecule drugs and large biologic proteins, combining the target specificity of antibodies with improved tissue penetration and lower manufacturing costs. The global peptide therapeutics market exceeded $50 billion in 2023 and is projected to grow at 9-10% annually.
What is Pharmacogenomics?Pharmacogenomics (PGx) is the study of how an individual's genetic makeup influences their response to medications. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, personalized drug therapies based on a patient's DNA.
What is Personalized Medicine?Personalized medicine (also called precision medicine) is a medical model that uses an individual's genetic, environmental, and lifestyle information to guide clinical decisions. Rather than prescribing the same drug at the same dose to every patient with a given condition, personalized medicine selects therapies and dosages based on the patient's unique biological profile — particularly their genomic data.
What is Binding Affinity?Binding affinity is a quantitative measure of the strength of interaction between two molecules, typically a drug (ligand) and its biological target (receptor or protein). It is most commonly expressed as the dissociation constant (Kd), which represents the concentration of ligand at which 50% of the target binding sites are occupied. A lower Kd indicates stronger binding — nanomolar (nM) or picomolar (pM) affinities are typical for effective drugs.
Related SNPs
Apply This Knowledge with PepFold
Submit rsIDs and get ranked peptide candidates with 3D structures and Fmoc-SPPS synthesis protocols in under 2 minutes.